ISPOR 14th European Congress

Download ISPOR 14th European Congress

Post on 10-Mar-2016

254 views

Category:

Documents

41 download

Embed Size (px)

DESCRIPTION

ISPOR is partnering with pharmacoeconomic and outcomes researchers and health care decision-makers from around the world to implement its outreach programs. There are currently 52 ISPOR Regional Chapters with 8 Chapters in development.

TRANSCRIPT

  • ISPOR 14th AnnuAl EuROPEAn COngRESS

    5-8 nOvEmbER 2011hOtEl AudItRIum mAdRId

    mAdRId, SPAIn

    international society for pharmacoeconomics and outcomes research

    Rational Health Care Decision Making in Challenging Economic Times

    fOR mORE InfO: www.ISPOR.ORg

    PROgRAmEarly rEgistration DEaDlinE: 20 sEptEmbEr 2011

    KEY InfORmAtIOn

    OVER 1500PRESENTATIONS22% INcREASE IN AbSTRAcTS SubmITTEd!

    CongrEss program CommittEE

    PROGRAM COMMITTEE CHAIRXavier Badia, phd, md, mph, Global Leader, Observational COE & Senior Principal, HEOR, IMS Health, Barcelona, Spain

    RESEARCH REVIEW COMMITTEE CO-CHAIRSJan J.V. Busschbach, phd, Interim Director, Department of Medical Psychology & Psychotherapy, Erasmus MC, Rotterdam, The Netherlandsdominik Golicki, md, phd, ma, Partner, HealthQuest sp z o.o., Warsaw, Poland michael schlander, phd, md, mBa, Chairman & Scientific Director, Institute for Innovation & Valuation in Health Care (InnoVal), Wiesbaden, Germanyerkki soini, msc, rn, Chief Executive Officer, ESiOR Ltd., Kuopio, Finland

    WORKSHOP REVIEW COMMITTEE CO-CHAIRSfernando antoanzas, ma, phd, Economist, Department of Economics, University of La Rioja, Logrono, Spain nancy J. devlin, phd, Director of Research, Office of Health Economics, London, UK

    ISSUE PANEL REVIEW COMMITTEE CO-CHAIRSpeter hertzman, phd, Executive Director, HEOR, BMS Europe, Rueil Malmaison, FranceJacco Keja, phd, Regional Leader, EMEA, HEOR, IMS Health, London, UK and Lecturer in Life Sciences Pricing and Management, Institute for Health Policy and Management, Erasmus University, Rotterdam, The Netherlands

    DECISION-MAKER CASE STUDY REVIEW COMMITTEE CHAIRantoni Gilabert perramon, phd, Managing Director of Pharmaceutical Care and Complementary Benefits, Catalan Health Service, Department of Health and Social Security, Government of Catalonia, Barcelona, Spain

    CongrEss promotional opportUntiEseXhiBit: Register now! Over 2900 attendees in 2010!adVertise: Advertise in the Program and Schedule of Events! sponsor: Give your company increased visibility and prominence!ADVERTISING DEADLINE: 16 September 2011

    rEsEarCH postEr prEsEntationsPOSTER SESSION I: SUNDAY, 6 NOVEMBERSet-Up: 11:30-12:00Poster Display Hours: 12:00-20:00Poster Author Discussion Hour: 18:15-19:15Dismantle: 20:00-20:30

    POSTER SESSION II: MONDAY, 7 NOVEMBERSet-Up: 7:30-8:00Poster Display Hours: 8:00-19:30Poster Author Discussion Hour: 17:30-18:30Dismantle: 19:30-20:00

    POSTER SESSION III: TUESDAY, 8 NOVEMBERSet-Up: 7:30-8:00Poster Display Hours: 8:00-16:00Poster Author Discussion Hour: 11:00-12:00 Dismantle: 16:00-16:30

    CongrEss VEnUE inFormation/ HotEl rEsErVationsHotel Auditrium MadridAvenida de Aragn, 400, 28022 MadridThe hotel is conveniently situated near the Madrid International Airport Barajas and is approximately 16 km (10 miles) from central Madrid.

    ispor rates: The discounted room rate for ISPOR congress attendees is r113 for single occupancy and r128 for double occupancy. These rates include applicable taxes and daily complimentary buffet breakfast. Delegate rates are available until the deadline of 6 November 2011 (subject to availability)reservations: Must be made using the Hotel Auditrium online reservation system available at www.ispor.org (Event name: ISPORNOV). Cancellations or changes to reservations without penalty must be made 30 days prior to arrival.

  • ISPOR 14th AnnuAl EuROPEAn COngRESS

    5-8 nOvEmbER 2011 n mAdRId, SPAIn SAtuRdAY, 5 nOvEmbER All dAY COuRSE (9:00-18:00)

    introduction to pharmacoeconomicslieven annemans, phd, mman, msc, Ghent University Brussels University, BelgiumThis course incorporates pharmacoeconomics into study design and data analysis. Participants collect and calculate costs of different alternatives, determine the economic impact of clinical outcomes, and identify, track and assign costs to different types of health care resources used.

    SAtuRdAY, 5 nOvEmbER mORnIng COuRSES (9:00-13:00)NEW! introduction to design & analysis of retrospective database studies michael Johnson, phd, College of Pharmacy, University of Houston, USA This course will provide an overview of analytic techniques and specific best practices to improve causal inference in retrospective database studies, including an introductory level discussion of causal graphs, stratification analysis, propensity scoring, instrumental variable and structural modeling techniques.

    introduction to patient-reported outcomes assessment: instrument development & evaluationandrew lloyd, dphil; annabel nixon, phd; & sarah acaster, msc, Oxford Outcomes, UKInstrument development and evaluation includes psychometric analyses such as the use of factor analysis and other techniques. This course will cover the recent draft guidance from the FDA as well as existing guidance from the EMEA regarding instrument development.

    introduction to modeling uwe siebert, md, mph, msc, scd, University of Health Sciences, Medical Informatics and Technology, Austria, & Harvard Medical School, Boston, MA, USAThis course presents an introductory discussion of pharmacoeconomic modeling techniques such as Monte Carlo analysis, Markov modeling, and probabilistic sensitivity analysis.

    discrete event simulation for economic analyses conceptsJ. Jaime caro, mdcm, fcrpc, facp, McGill University & United BioSource Corporation, USA; Jrgen mller, msc mech eng, United BioSource Corporation, SwedenTopics to be covered are: How does it work, what are the components of a DES, where is it used, for which problems is DES well suited, what are the advantages and disadvantages of DES, PSA as a simple task.

    Bayesian methods in economic evaluations introduction christopher s. hollenbeak, phd, Penn State College of Medicine, USA This course provides an overview of the Bayesian approach and its applications to health economics and outcomes research. It covers basic elements of Bayesian statistics, contrasting briefly with classical (frequentist) statistics and introduces available statistical packages.

    statistical methods for pharmacoeconomics & outcomes researchandrew Briggs, phd, University of Glasgow, UK; neil hawkins, phd, msc, University of York, UKAn introduction to statistical methods with an emphasis on the use of techniques commonly employed in pharmacoeconomics and outcomes research is given. Key considerations for planning and analyzing studies and interpreting results will be reviewed. Differences between a classical (frequentist) approach to statistics and a Bayesian view of probability are discussed.

    cost-effectiveness analysis alongside clinical trialsscott ramsey, md, phd, Fred Hutchinson Cancer Research Center, USA; sean sullivan, phd, msc, University of Washington, USA; richard Willke, phd, Pfizer, Inc, USA This course will present the design, conduct, and reporting of cost-effectiveness analyses alongside clinical trials. Trial design, selecting data elements, database design and management, analysis, and reporting of results will be presented.

    elements of pharmaceutical/Biotech pricing i introduction Jack m. mycka, Global MME LLC, USA; renato dellamano, phd, MME Europe & ValueVector, Italy This course gives participants a basic understanding of the key terminology and issues involved in pricing decisions. It covers the tools to build and document product value, the role of pharmacoeconomics and the differences in payment systems that help to shape pricing decisions.

    SAtuRdAY, 5 nOvEmbER AftERnOOn COuRSES (14:00-18:00)meta-analysis & systematic literature reviewneil hawkins, phd, msc, University of York, UK; olivia Wu, phd, msc, University of Glasgow, UKThis course highlights and expounds upon four key areas: 1) impetus for meta-analysis and systematic reviews; 2) basic steps to perform a quantitative systematic review; 3) statistical methods of combining data; and 4) appraisal and use of meta-analytic reports.

    applications in using large european databasesJohn parkinson, phd, GPRD, UK; ron herings, phd, pharmd, Pharmo, The Netherlands; rob thwaites, ma, mcom, United BioSource Corporation, UKThis course evaluates European health care databases, discussing each in-depth with directions on how to access information and how researchers utilize this information. The ISPOR International Digest of Databases - a tool that identifies databases around the world for research purposes - will be discussed.

    patient registriesleanne larson, mha, Outcome, USA; michelle Bulliard, rn, Bscn, micr, Outcome, Switzerland; elizabeth hernberg-stahl, msc, Late Phase Solutions Europe AB, SwedenThis course reviews patient registries and their applications in identifying real world clinical, safety, and patient-perspective issues. The pros and cons of registry data and how it can support health economics/outcomes research initiatives and decision making are addressed. Registry strategy, design, operations and measures of program success are discussed.

    advanced retrospective database analysisWilliam h. crown, phd, Optum Insights, USAThis course discusses the ISPOR Checklist for Retrospective Database Studies and selected topics related to estimators and sampling distributions, properties of sampling distributions, and ordinary least squares (OLS) regression.

    utility measurements (preference-Based techniques)Jan Busschbach, phd, Erasmus Medical Center & Viersprong Institute for Studies on Personality Disorders, The NetherlandsMethods for measuring preference-based outcomes and important issues are reviewed, such as: potential insensitivity of generic instruments for disease-specific problems, and to what extent adaptation of generic or disease-specific quality of life instruments may offer a solution.

    pharmacoeconomic modeling applicationsmark s. roberts, md, mpp, University of Pittsburgh Graduate School of Public Health, USAStudents will have hands-on experience in constructing a decision analysis tree including Markov models, Monte Carlo simulations, sensitivity analysis, determination of probability values and transition probabilities. This course is a follow-up to Introduction to Modeling.

    discrete event simulation for economic analyses applicationsJ. Jaime caro, mdcm, fcrpc, facp, McGill University & United BioSource Corporation, USA; Jrgen mller, msc mech eng, United BioSource Corporation, Sweden Topics to be covered are: Components of a DES; How do you build a model? Modeling of processes and resource use; Modeling of variables and decisions. Simple animation will be demonstrated using ARENA software.

    introduction to health technology assessment (hta)uwe siebert, md, mph, msc, scd, University of Health Sciences, Medical Informatics and Technology, Austria, & Harvard Medical School, USAThis course introduces key elements, methods and language of health technology assessment (HTA) and provides an overview of basic HTA disciplines. Using real world examples, the course

    reviews the practical steps involved in developing and using HTA reports in different countries and health care systems.

    SundAY, 6 nOvEmbER mORnIng COuRSES (8:00-12:00)

    Bayesian methods in economic evaluations advanced Keith r. abrams, phd, University of Leicester, UKThis course covers the differences between Bayesian and classical approaches, and the application of Bayesian analysis to clinical trials and cost-effectiveness analyses.

    reimbursement systems in europeJames furniss; sasha richardson, mBa; & timothy fitzgerald, Bridgehead International, UKThis course reviews procedures employed by European health authorities to regulate market access. Faculty describe reimbursement legislation, processes and organizations of various countries and describe the role of the pharmaceutical and/or medical device manufacturer.

    risk-sharing/performance-Based arrangementsadrian towse, ma, mphil, Office of Health Economics, UK; lou Garrison, phd; & Josh carlson, phd, University of Washington, USA Theory and practice, including incentives and barriers, of these arrangements are analyzed using examples of performance-based schemes from Europe, the United States, and Australia.

    case studies in pharmaceutical/Biotech pricing ii advancedJack m. mycka, MME LLC, USA; renato dellamano, phd, MME Europe & ValueVector, Italy Case studies analyze new product pricing, focusing on the need to thoroughly evaluate the business environment and the need to integrate pricing, reimbursement and pharmacoeconomics strategies with clinical development and marketing strategies.

    transferability of cost-effectiveness data between countriesJl (hans) severens, phd; smaa evers, phd ll.m; & ma Joore, phd, Maastricht University, The Netherlands This course discusses factors that make economic data more difficult to transfer from one country to another than clinical data, and the evidence on the variability of cost-effectiveness results across countries. We will review the methods that offer a solution and their pros and cons. Finally, we will discuss emerging international guidance for dealing with issues of transferability.

    cost estimation and assessing financial (Budget) impact of new health care technologiesJosephine mauskopf, phd, RTI Health Solutions, USA; c. daniel mullins, phd, University of Maryland, USA Learn methods to determine the cost-of-illness of a health condition using a top-down or bottom-up approach. Learn how to estimate the impact of new health care technologies.

    NEW! establishing the content Validity of patient-reported outcome (pro) instruments donald l. patrick, phd, msph, University of Washington; mona l. martin, rn, mpa, Health Research Associates, Inc.; chad Gwaltney, phd, Brown University, USA Requirements for establishing content validity of PRO instruments, definitions of evidence requirements, issues necessitating clarity, and logistical needs for gathering acceptable evidence are covered. Practical exercises are used to establish evidence of content validity for PRO instruments.

    NEW! conjoint analysis theory & methodsa. Brett hauber, phd, RTI Health Solutions, USA; John f. p. Bridges, phd, Johns Hopkins Bloomberg School of Public Health, USA Discuss the conceptual basis for quantifying decision maker preferences for medical interventions and practical design and analytical issues that must be addressed to obtain valid empirical preference estimates.

    NEW! network meta-analysis in relative effectiveness research Jeroen p. Jansen, phd, Mapi Values, USA The fundamentals and concepts of network meta-analysis will be presented and proposed. Case studies are implemented with the WinBUGS package. This course requires basic knowledge of meta-analysis and statistics.

    2 Full Short course descriptions at www.ispor.org

  • ISPOR 14th AnnuAl EuROPEAn COngRESS

    5-8 nOvEmbER 2011 n mAdRId, SPAIn

    3

    SAtuRdAY, 5 nOvEmbER

    9:00-18:00 PRE-CONGRESS SHORT COURSES

    18:15-19:15 EDUCATIONAL SYMPOSIUM ValuinG innoVation: should innoVation Be considered in pricinG and reimBursement of health care technoloGies?This symposium will discuss ways of defining and measuring innovati...

Recommended

View more >